Poseida Therapeutics, Inc. (PSTX)
Stock Price:
$11.07 USD
-0.15 (-1.34%)
Updated November 24, 2:52 PM EST - Market open
Key Info
| Market Cap |
684.35M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
n/a |
| Shares Out |
61.82M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 24 |
| Last Price |
$11.07 |
| Previous Close |
$11.22 |
| Change ($) |
-0.15 |
| Change (%) |
-1.34% |
| Day's Open |
11.22 |
| Day's Range |
10.82 - 11.41 |
| Day's Volume |
36,317 |
| 52-Week Range |
7.63 - 17.62 |
More Stats
| Market Cap |
684.35M |
| Enterprise Value |
401.76M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
61.82M |
| Float |
23.86M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.00M |
| Short Ratio |
8.76 |
| Short % of Float |
4.21% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
11.97 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
282.58M |
| Net Cash / Share |
4.57 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$25.00*
(125.84% upside)
Low
20.0
Current: $11.07
High
30.0
Target: 25.00
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -85.53 | -41.99 |
| Net Income | -86.53 | -44.40 |
| Shares Outstanding | 12.62 | 12.18 |
| Earnings Per Share | -6.86 | -3.64 |
| Operating Cash Flow | -64.39 | -38.01 |
| Capital Expenditures | -5.16 | -1.28 |
| Free Cash Flow | -69.55 | -39.30 |
| Cash & Equivalents | 125 | 30.40 |
| Total Debt | 29.14 | 19.09 |
| Net Cash / Debt | 96.18 | 11.31 |
| Assets | 147 | 45.12 |
| Liabilities | 74.33 | 49.38 |
| Book Value | -150 | -76.72 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Poseida Therapeutics, Inc. |
| Country |
United States |
| Employees |
186 |
| CEO |
Eric M. Ostertag |
Stock Information
| Ticker Symbol |
PSTX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: PSTX |
| IPO Date |
July 10, 2020 |
Description
Poseida Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Further, it offers gene therapies for rare and life-threatening diseases, including Ornithine transcarbamylase (OTC) deficiency and methylmalonic acidemia (MMA), and genetic liver diseases. The company was founded in 2014 and is headquartered in San Diego, California.